Bishop graces Genesis board
This article was originally published in Scrip
Hans Bishop has joined the board of Genesis Biopharma, a biotech developing targeted cancer immunotherapies, bringing the total number of board members to eight. Most recently, Mr Bishop served as chief operating officer for Dendreon. Prior to that, he was president of the specialty medicine business unit at Bayer Healthcare.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.